Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE: PFE), today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Akcea Therapeutics (AKCA) PT Trimmed to $39 at BMO Capital; Pfizer Deal Provides 'Immediate Value'October 7, 2019 12:25 PM Akcea Therapeutics, Inc. (AKCA) ANGPTL3 Deal with Pfizer 'Strong' - Needham & CompanyOctober 7, 2019 11:39 AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)October 7, 2019 6:50 AM